Emerging analyses on retatrutide, a dual agonist for incretin hormone and glucose-dependent insulinotropic polypeptide, demonstrate encouraging outcomes in managing obesity and type 2 diabetes. Initial evidence from clinical trials point to notable diminutions in body bulk and improved glucose co